Uterine Microbiome in Recurrent Pregnancy Loss
Reproductive Tract Microbiome in Women With Recurrent Pregnancy Loss
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tuong M Ho, MD, MCE
- Phone Number: (+84) 903 633 377
- Email: bstuong.hm@myduchospital.vn
Study Contact Backup
- Name: Nam T Nguyen, MD
- Phone Number: +84354120209
- Email: bsnam.nt@myduchospital.vn
Study Locations
-
-
Ho Chi Minh City
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 70000
- Recruiting
- My Duc Hospital
-
Contact:
- Vu NA Ho, MD
- Phone Number: +84935843336
- Email: bsvu.hna@myduchospital.vn
-
Contact:
- Nam T Nguyen, MD
- Phone Number: +84354120209
- Email: bsnam.nt@myduchospital.vn
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 70000
- Recruiting
- My Duc Phu Nhuan Hospital
-
Contact:
- Tien K Le, MD
- Phone Number: +84962803875
- Email: bstien.lk@myduchospital.vn
-
Contact:
- Ho L Le, MD
- Phone Number: +84356177147
- Email: bsho.ll@myduchospital.vn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Recurrent pregnancy loss patients
Inclusion Criteria:
- 18-38 years old
- Having a regular menstrual cycle, from 25 to 35 days
- Having ≥ 2 recurrent pregnancy loss and
- Couples with normal karyotype results
- Having no condition causing pregnancy loss such as antiphospholipid syndrome, abnormal thyroid function.
- Agree to participate in the study
Exclusion Criteria:
- Irregular menstrual cycle
- Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal fibroid)
- Using intrauterine device within the last 3 months
- Using antibiotic/vaginal pessary/contraceptive pills within 2 weeks
- Having sexual intercourse within 48 hours
- Healthy control patients
Inclusion Criteria:
- 18-38 years old
- Having a regular menstrual cycle, from 25 to 35 days
- No history of pregnancy loss
- Having 1 or more live birth, with the youngest child ≥ 6 months old
- Agree to participate in the study
Exclusion Criteria:
- Irregular menstrual cycle
- Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal fibroid)
- Using intrauterine device within the last 3 months
- Using antibiotic/vaginal pessary/contraceptive pills within 2 weeks
- Having sexual intercourse within 48 hours
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Recurrent pregnancy loss
Women with history of recurrent pregnancy loss
|
A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
|
|
Control
Normal fertile women
|
A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Midluteal bacterial composition of endometrium in women with recurrent pregnancy loss and control group
Time Frame: 1 week
|
Bacterial composition in the endometrium in midluteal phase are analysed using 16S rRNA gene sequencing
|
1 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Midluteal bacterial composition of vagina in women with recurrent pregnancy loss and control group
Time Frame: 1 week
|
Bacterial composition in the vaginal in midluteal phase are analysed using 16S rRNA gene sequencing
|
1 week
|
|
Phylogenetic tree of endometrial microorganisms in women with recurrent pregnancy loss and control group
Time Frame: 1 week
|
Phylogenetic tree based on 16S rRNA gene sequences
|
1 week
|
|
Phylogenetic tree of vaginal microorganisms in women with recurrent pregnancy loss and control group
Time Frame: 1 week
|
Phylogenetic tree based on 16S rRNA gene sequences
|
1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Lan N Vuong, MD, PhD, University of Medicine and Pharmacy at Ho Chi Minh City
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 05/22/DD-BVMD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.